A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Trial Profile

A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Peginterferon lambda-1a (Primary)
  • Indications Hepatitis D
  • Focus Therapeutic Use
  • Acronyms LIMT; LIMT HDV
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 02 Oct 2017 According to an Eiger BioPharmaceuticals, Inc. media release, 24 week interim data from the study will be presented at the American Association for the Study of Liver Diseases (AASLD) 2017.
    • 24 Jul 2017 Status changed from recruiting to active, no longer recruiting according to an Eiger BioPharmaceuticals media release.
    • 31 May 2017 Planned number of patients changed from 30 to 40.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top